Enalapril mechanism of action
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Enalapril Mechanism of Action
Introduction to Enalapril and ACE Inhibition
Enalapril is a long-acting, orally active angiotensin-converting enzyme (ACE) inhibitor extensively hydrolyzed in vivo to its bioactive form, enalaprilat. This conversion primarily occurs in the liver, and the drug is primarily excreted through the kidneys. Enalapril functions by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and alleviating strain on the cardiovascular system.
Impact on Cardiovascular Health
Blood Pressure Reduction and Vascular Effects
Enalapril effectively lowers peripheral vascular resistance without causing an increase in heart rate. This reduction in blood pressure is achieved through decreased systemic vascular resistance, which is not accompanied by an increase in heart rate, thus maintaining cardiovascular reflexes . Additionally, enalapril increases renal blood flow and decreases renal vascular resistance, which contributes to its antihypertensive effects.
Anti-Inflammatory and Anti-Atherosclerotic Properties
Enalapril has been shown to prevent atherosclerosis and vascular inflammation induced by angiotensin II. It achieves this by preventing the over-expression of endothelial adhesion molecules and chemokines, which are critical in the development of atherosclerosis. Furthermore, enalapril up-regulates the expression of peroxisome proliferator-activated receptors (PPARs)-alpha and -gamma, which are potential anti-inflammatory transcription factors. This suggests that enalapril's benefits extend beyond blood pressure reduction to include significant anti-inflammatory and anti-atherogenic effects.
Cellular and Molecular Mechanisms
Modulation of Endothelial Progenitor Cells (EPCs)
Enalapril increases the mobilization of endothelial progenitor cells (EPCs) in response to ischemic stress. This is mediated through the CD26/dipeptidylpeptidase IV (DPP IV) system, which plays a role in the regulation of EPC numbers. Enalapril's modulation of this system results in a significant increase in circulating EPCs, contributing to neovascularization and cardiovascular repair mechanisms.
Inhibition of NF-κB Signaling Pathway
Enalapril inhibits the nuclear factor-kappa B (NF-κB) signaling pathway, which is crucial in the inflammatory response. This inhibition reduces the production of pro-inflammatory cytokines such as IL-8, TNF-α, IL-6, and IL-12 in intestinal epithelial cells and peritoneal macrophages. Consequently, enalapril attenuates experimental colitis in mice, highlighting its potential therapeutic role in inflammatory conditions.
Effects on Renal Function and Oxidative Stress
Enalapril has been shown to ameliorate diabetic nephropathy by reducing oxidative stress and improving the antioxidant defense system. It decreases the levels of pro-inflammatory cytokines and apoptotic mediators while increasing the expression of anti-apoptotic proteins. This results in improved kidney function and reduced histopathological damage in diabetic rats.
Conclusion
Enalapril's mechanism of action extends beyond simple ACE inhibition. It involves a complex interplay of cardiovascular, anti-inflammatory, and cellular effects. By reducing blood pressure, preventing atherosclerosis, modulating EPC mobilization, inhibiting NF-κB signaling, and improving renal function, enalapril offers a multifaceted approach to treating hypertension and related cardiovascular conditions. These diverse mechanisms underscore its therapeutic potential in managing a wide range of cardiovascular and inflammatory diseases.
Sources and full results
Most relevant research papers on this topic